Setonix Pharmaceuticals has described peroxisome proliferator-activated receptor γ (PPARγ) modulators reported to be useful for the treatment of inflammatory disorders, metabolic syndrome, obesity, viral infection, cancer, lipid metabolism and glucose metabolism disorders.